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Human pathologies such as vascular malformations, hemorrhagic stroke, and edema have been associated
with defects in the organization of endothelial cell junctions. Understanding the molecular basis of these
diseases requires different integrated approaches which include basic cell biology, clinical studies, and
studies in animal models such as mice and zebrafish. In this review we discuss recent findings derived
from these approaches and their possible integration in a common picture.A variety of human vascular pathologies are due to or exacer-
bated by altered control of endothelial permeability. Defects in
endothelial permeability can lead to edema and increase in inter-
stitial pressure, which in turn induces compression and altered
tissue perfusion. A typical example is ischemic stroke, where
edema around the ischemic area extends brain damage. Inflam-
mation is also associated with increases in vascular perme-
ability, which favors leukocyte diapedesis through the vessel
wall but may create pain and swelling. Edema is usually a revers-
ible condition and the control of vascular permeability may be
restored once the triggering cause is removed.
However, there are extreme conditions where the integrity of
the endothelial monolayer is severely affected, cell-to-cell junc-
tions are disrupted, and endothelial cells detach from the vessel
wall, creating areas of vascular damage and possibly micro-
thrombi. Altered permeability may also be accompanied by
vascular fragility with the frank rupture of the vessels and forma-
tion of hemorrhages. This is a frequent condition in tumors where
the newly forming vasculature is usually permeable and fragile
(Carmeliet and Jain, 2000). In other more rare cases though,
increased vascular fragility may be due to congenital alterations
in vascular development (Brouillard and Vikkula, 2003, 2007).
Molecular cloning of the defective genes from human disorders
and gene inactivation approaches in model organisms such as
mouse and fish have resulted in the identification of many genes
involved in vascular remodeling and maintenance of vascular
integrity. Deletion or reduced expression of these genes may
result in early lethality due to diffuse hemorrhages in the embryo.
However, in other cases the vascular defect may remain silent
during development but manifest in the adult when the vessels
are exposed to a triggering condition.
Defects in vascular permeability can have a number of
different causes. Vascular permeability is mediated by at least
two broad mechanisms, called the paracellular and transcellular
pathways. The first is controlled by the dynamic opening and
closing of endothelial junctions (Dejana et al., 2008), while thesecond includes vesicular transport systems, fenestrae, and
biochemical transporters (Dvorak et al., 1996). Vascular fragility
can be due to an altered organization of intercellular junctions
and/or defective interaction of endothelial cells with pericytes
or matrix proteins. The focus of this review is primarily on the
role of intercellular junctions in the control of vascular perme-
ability and integrity. We discuss current knowledge regarding
the molecular and functional organization of adherens (AJ) and
tight junctions (TJ), and attempt to show the correlations
between experimental studies and related human pathologies.
The Molecular Organization of Endothelial Cell-to-Cell
Junctions
The detailed architecture of endothelial cell-cell junctions has
been described in detail in several other recent reviews (Bazzoni
and Dejana, 2004; Gonzalez-Mariscal et al., 2008; Wallez and
Huber, 2008) In Figure 1 we show a simplified version of some
of the most important molecules involved in endothelial junction
organization (Bazzoni and Dejana, 2004; Vestweber, 2008;
Weber et al., 2007). Endothelial cells have at least two special-
ized adhesive junctional regions that are comparable to adhe-
rens junctions (AJs) and tight junctions (TJs) found in epithelial
cells. In contrast to epithelial cells, however, endothelial cells
lack typical desmosomes. Gap junctions are also present in
the endothelium and play an important role in different endothe-
lial functions but, as far as we know, are not involved in control of
endothelial permeability and, for simplicity, will not be further
considered in this review.
AJs and TJs have different functions. AJs initiate cell-to-cell
contacts and promote their maturation and maintenance. TJs
regulate the passage of ions and solutes through the paracellular
route (Bazzoni and Dejana, 2004; Gonzalez-Mariscal et al.,
2008). TJs may also act as a membrane ‘‘fence’’ to limit the
free movement of lipids and proteins between the apical and
the basolateral cell surfaces. Most importantly, both structures
can transfer intracellular signals that control many endothelialDevelopmental Cell 16, February 17, 2009 ª2009 Elsevier Inc. 209
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ReviewFigure 1. Schematic Representation of
Tight Junctions and Adherens Junctions
in Endothelial Cells
In endothelial cells, adhesion at tight junctions is
mediated by claudins, occludin, members of the
JAM family, and ESAM. The cytoplasmic compo-
nents of tight junctions are ZO proteins, cingulin,
ZONAB, and others. At adherens junctions, adhe-
sion is promoted by cadherins (VE-cadherin and
N-cadherin) which directly bind to p120, b-cate-
nin, and plakoglobin. Nectins and their intracellular
partner afadin/AF-6 participate in the organization
of both tight and adherens junctions (Takai et al.,
2008). A large set of actin binding proteins have
been found to be associated to adherens junctions
such as a-catenin, vinculin, a-actinin, eplin,
and others. In addition, phosphatases (DEP-1,
VE-PTP, PTPm, SHP2, etc.) and kinases (src, csk,
and others) are directly or indirectly associated
to adherens junction components. Growth factor
receptors: VEGF receptor 2 (also called flk-1 or
KDR) and TGFb receptor complex could bind to
VE-cadherin complex. This interaction modulates
their signaling properties. More details can be
found in the text and, for review, in the following:
Bazzoni and Dejana, 2004; Dejana, 2004; Engel-
hardt, 2003; Furuse and Tsukita, 2006; Gonzalez-
Mariscal et al., 2008; Johnson-Leger and Imhof,
2003; Matter and Balda, 2003; Van Itallie and
Anderson, 2006; Wallez and Huber, 2008; and
Vestweber, 2008.cell functions. The organization of intercellular junctions through
the clustering of adhesion and signaling proteins is therefore an
important process through which the cells sense their position,
control growth and apoptosis, and form tubular structures (see
below) (Matter and Balda, 2003; Bazzoni and Dejana, 2004;
Dejana, 2004; Gonzalez-Mariscal et al., 2008).
Although the molecular components of TJs and AJs are
different, they do have common features (Figure 1). In both types
of junction, adhesion is mediated by transmembrane proteins
that promote homophilic interactions and form a pericellular
zipper-like structure along the cell border through their lateral
aggregation in trans and cis (for review Bazzoni and Dejana,
2004; Gonzalez-Mariscal et al., 2008; Wallez and Huber, 2008)
Endothelial cells express cell-type-specific transmembrane
adhesion proteins such as VE-cadherin at AJs and claudin-5 at
TJs. The restricted cell specificity of these components indicates
that they might be needed for selective cell-cell recognition and/
or specific functional properties of endothelial cells. Through
their cytoplasmic tails, adhesion proteins of both types of junc-
tions bind to cytoskeletal and signaling proteins that promote
anchoring of junctions to actin microfilaments and transfer of
intracellular signals to the inside of the cell. Cytoskeletal associ-
ation is required for stabilization of the junctions, but also for the
dynamic regulation of junction opening and closing. The interac-
tion of junctional adhesion proteins with the actin cytoskeleton is
also relevant in the maintenance of cell shape and polarity
(Hartsock and Nelson, 2008). Many reports support the concept
that AJs and TJs are interconnected and that AJs influence
TJ organization (see below). AJs are formed at early stages of
intercellular contacts and are followed by TJ organization.
Some TJ components such as ZO-1 are found in AJs at early
stages of junction formation and concentrate in TJs only subse-
quently when junctions are stabilized. Interestingly, however,210 Developmental Cell 16, February 17, 2009 ª2009 Elsevier Inc.AJs are required for TJ assembly but are dispensable for
TJ maintenance in epithelial cells (Capaldo and Macara, 2007).
As described in the legend to Figure 1, the core components of
TJs that promote cell-to-cell adhesion are members of the clau-
din family (Van Itallie and Anderson, 2006; Furuse and Tsukita,
2006). The claudin family has more than 20 members, only
a few of which are expressed by endothelial cells. Claudin-5 is
rather ubiquitous along the vascular tree. Other non-cell-specific
claudins are also found in endothelial cells and their combination
varies to respond to the different needs of the perfused organ. A
variety of additional adhesion transmembrane proteins can also
be found at TJs (JAMs, ESAM, occludin, etc.) and these
contribute to intercellular adhesion in different ways (see below)
(Wallez and Huber, 2008). Multiple intracellular partners of
TJ adhesive proteins have been described. Among the best
characterized are the members of the ZO family (ZO1 and 2 in
the endothelium), a closely related subgroup of the membrane
associated guanylate kinase (MAGUK) family that localize at
TJs in most tissues including the endothelium. Other intracellular
TJ proteins include signaling and actin-binding proteins. At
AJs, adhesion is mediated by members of the cadherin family.
VE-cadherin is expressed in essentially all types of vessels.
N-cadherin is also present in the endothelium, but is frequently
found localizing to non-AJ cellular structures both in vitro and
in vivo. VE- and N-cadherins both bind catenins, in particular
p120, b-catenin, and plakoglobin. b-catenin also binds a-cate-
nin, which when released from junctions into the cytosol
promotes actin bundling. As for TJs, many other actin-binding
proteins and several kinases and phosphatases are also found
at AJs (Wallez and Huber, 2008; Bazzoni and Dejana, 2004;
Vestweber, 2008).
The organization of TJs and AJs varies along the vascular tree
depending on the functional needs of the vessels. For instance,
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culation where there is a need to strictly control permeability,
whereas the junctions are relatively poorly organized in postca-
pillary venules where exchange between blood and tissues is
quite dynamic (Engelhardt, 2003; Dejana, 2004). An example of
highly specialized junctions is found in peripheral lymphatic
vessels, where intercellular junctions between lymphatic endo-
thelial cells control entry of fluid and cells that drain from
surrounding tissues. These lymphatic capillaries possess highly
specialized junctions that, although formed by the same molec-
ular components as blood vessels, have a strikingly different
morphology. Endothelial borders have discontinuous button-
like junctions with intermingled flaps resembling valve-like
structures (Baluk et al., 2007). At the molecular level, AJ and
TJ proteins are concentrated at the buttons, leaving the flaps
free to open without disrupting the overall junctional organiza-
tion. The larger, more proximal collecting lymphatic vessels
have continuous zipper-like junctions resembling those in the
endothelium of blood vessels.
The Dynamic Regulation of Vascular Permeability
An important emerging concept is that intercellular junctions are
dynamic structures undergoing continuous remodeling not only
during morphogenesis in the embryo or upon exposure of cells to
agents that increase permeability, but also in confluent and
resting cells. Continuous recycling of adhesive proteins and
signaling partners may occur at AJs and also at TJs. Cadherins,
and in particular VE-cadherin, show a flow-like movement in
a basal to apical direction which is accompanied by actin reorga-
nization (Kametani and Takeichi, 2007). Furthermore, recent data
have shown that in Drosophila E-cadherin forms stable adhesion
foci that undergo continuous, actin-controlled, mobility along
intercellular contacts (Cavey et al., 2008). All of this suggests
that even apparently stable AJs are dynamic structures able to
continuously adapt to tissue requirements. The endothelium is
continuously exposed to hemodynamic stimuli such as shear
stress or the rhythmic changes in pressure due to heart beating,
as well as vessel contraction and dilation. Junctions and the
cell cytoskeleton need to continuously reshape to allow the
endothelial monolayer to adapt to the dynamic conditions to
which it is exposed. Junctional proteins such as VE-cadherin
may also serve as flow sensors and transfer intracellular stimuli
which help the cell to react to changes in flow conditions (Tzima
et al., 2005).
TJs and Permeability Control
As discussed above, the role of junctions in endothelial and
epithelial cell permeability is now well established, and these
are clearly highly dynamic structures regulated in response to
environmental conditions. A number of recent studies have
focused on the importance of claudins in TJ formation and main-
tenance (Furuse and Tsukita, 2006; Van Itallie and Anderson,
2006). Although inactivation of claudin-5 gene in mice did not
morphologically alter the vascular network or the ultrastructural
appearance of TJs, claudin-5-deficient pups died within 10 hr
of birth due to a size-selective loosening of the blood-brain
barrier against molecules less than 800 Da. Other claudins may
form the TJ strands in claudin-5 mutants and maintain the barrier
against larger molecules (Furuse and Tsukita, 2006). Claudin-3 is
likely responsible for the complex organization of TJ in brainvessels. Claudin-3 and -5 therefore appear to act in concert to
form the tightly organized strand network at TJs of the brain
microcirculation. Gene inactivation of claudin-1, which is also
expressed in endothelial cells, did not result in a vascular pheno-
type during embryonic development, suggesting that it plays
a lesser role in TJ in endothelium compared to claudin-5 and
-3 (Gonzalez-Mariscal et al., 2008). Occludin is another trans-
membrane protein structurally similar to claudins, although not
strongly homologous at the sequence level, which becomes
incorporated into claudin-based junctional strands. Occludin is
present in endothelial cells and in particular in the brain (Hirase
et al., 1997). However, no effects on vascular morphology or
blood-brain barrier permeability have been reported in mice
lacking occludin.
Junction adhesion molecule-A (JAM-A) and its related family
members JAM-B, JAM-C, endothelial cell-selective adhesion
molecule (ESAM), and cocksackie- and adeno-virus receptor
(CAR) are transmembrane glycoproteins that associate with
TJ strands but are not part of the strands per se (Weber et al.,
2007). All JAM family members and ESAM are expressed in
endothelial cells, but inactivation of their respective genes in
mice does not cause any defect in the development of the
vascular system in the embryo (Weber et al., 2007; Wegmann
et al., 2006). In adult mice, all these molecules play an important
role in modulating leukocyte diapedesis through endothelial
cells. Unlike other junctional proteins, JAM-C increases endo-
thelial permeability when expressed at the endothelial cell
surface, suggesting it may play a role in promoting and/or orga-
nizing junction formation (Orlova et al., 2006). This activity is
mediated by changes in actin organization and VE-cadherin
activity. Several kinases and phosphatases have been shown
to modulate TJ protein phosphorylation and endothelial perme-
ability in vitro and in some conditions also in vivo.
The Role of AJs and VE-Cadherin in Vascular
Permeability
AJs, and the AJ component VE-cadherin in particular, play an
important role in the control of vascular permeability and integrity.
In vivo data using blocking antibodies to VE-cadherin show
profound alterations of lung and heart vascular permeability
accompanied by endothelial cell retraction and partial detach-
ment with exposure of the subendothelial matrix (for review see
Dejana et al., 2008). Stimuli such as high concentrations of hista-
mine, thrombin, or growth factors may increase endothelial cell
permeability through an effect on cell contractility mediated by
phosphorylation of myosin light chain and activation of p21-acti-
vated kinase (PAK) (Stockton et al., 2004). However, increased
permeability in vitro and in vivo could also be observed in the
presence of more subtle changes in AJ organization. Histamine,
tumor necrosis factor, platelet activating factor, and vascular
endothelial growth factor (VEGF) induce tyrosine phosphorylation
of VE-cadherin, b-catenin, and p120. This phosphorylation of
AJ proteins parallels increases in permeability in cell culture
systems (Dejana et al., 2008). Src is likely implicated in phosphor-
ylation of AJs as it is directly associated with the VE-cadherin/
catenin complex, and src gene inactivation or treatment with
inhibitors blocks VEGF-induced VE-cadherin phosphorylation
(Weis et al., 2004). VE-cadherin may also be phosphorylated
through inhibition of associated phosphatases. The phosphatase
VE-PTP is of particular interest as it is endothelial-specific andDevelopmental Cell 16, February 17, 2009 ª2009 Elsevier Inc. 211
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ReviewFigure 2. Protein Complexes that
Associate with VE-Cadherin and Other
Cadherins and Contribute to Adherens
Junction Stability
VE-cadherin binds to PAR-3 through its PDZ
domain and PAR3 can associate with PAR6 (Vest-
weber, 2008); the small GTPase Rap-1 stabilizes
adherens junctions and is activated by increase
in cAMP through Epac. Rap1 can bind the Rac-
GEF Tiam (Michiels et al., 1995) which was found
to codistribute with VE-cadherin complex (Lamp-
ugnani et al., 2002); CCM1,CCM2, and CCM3
form a complex which may associate to cadherins
via b-catenin or Rap1 (Serebriiskii et al., 1997;
Glading et al., 2007; Voss et al., 2007). For
simplicity, other potential partners of the complex,
such as ICAP-1 or afadin/AF6, are not illustrated in
the figure. More details can be found in the text.associates with VE-cadherin. Inactivation of the VE-PTP gene
leads to a phenotype comparable to that of VE-cadherin null
embryos. This suggests that vessels cannot form correctly if
VE-cadherin is constantly phosphorylated (Baumer et al., 2006).
Other phosphatases such as Dep-1, PTP-m, and SHP2 may
also associate with VE-cadherin and, directly or indirectly,
decrease phosphorylation and increase barrier function (Dejana
et al., 2008). There are also other kinases besides src that
may be associated with the VE-cadherin/catenin complex and
modulate permeability. This includes Csk, which binds to phos-
phorylated VE-cadherin and inhibits Src (Vestweber, 2008).
Permeability may also be regulated by VE-cadherin internaliza-
tion. VE-cadherin can be internalized in a clathrin-dependent
manner. Binding of p120 to VE-cadherin prevents internalization,
suggesting that p120 may act as a plasma membrane retention
signal. Therefore, any condition that reduces VE-cadherin affinity
for p120, such as tyrosine phosphorylation, may increase its
internalization. A recent report found that VEGF disrupts endo-
thelial barrier function by activating src, which in turn phosphory-
lates Vav2, a guanine exchange factor for Rac. Activated Rac
induces VE-cadherin phosphorylation in Ser665. This process
induces the recruitment of b-arrestin 2, which promotes clathrin
dependent VE-cadherin internalization. In this scenario, phos-
phorylation of VE-cadherin in Ser665 together with tyrosine
would be the crucial step for increase in permeability (Gavard
and Gutkind, 2006). Importantly, the same authors found that an-
giopoietin 1, which in many conditions reduces vascular perme-
ability, induces src trapping by mDia, reducing its activity at
AJs (Gavard et al., 2008).
Another pathway that may induce vascular permeability is
VE-cadherin cleavage. The VE-cadherin protein is particularly
susceptible to enzymatic proteolysis. Exposure to elastase,
Adam-10, and others induces digestion of VE-cadherin in
cultured cells (for review see Dejana et al., 2008). Leukocytes
and tumor cells can release high amounts of these enzymes,
promoting VE-cadherin cleavage and thus increasing cell extrav-
asation and vascular leakage. Permeability control may also be
achieved through up or downregulation of VE-cadherin expres-
sion. Analysis of the VE-cadherin promoter showed different
binding sites for several transcription factors known to act in212 Developmental Cell 16, February 17, 2009 ª2009 Elsevier Inc.endothelial cell differentiation. Among these TAL-1, Ets-1,
ERG, or hypoxia inducible factors were found to effectively
upregulate VE-cadherin (Birdsey et al., 2008; Deleuze et al.,
2007). Although VE-cadherin is present in high molecular number
on cultured endothelial cell membranes (more than 9 3 105 per
cell), its concentration may change in different types of vessels
in vivo and a modification in its expression may modify vascular
barrier function.
cAMP and Rap-1
It is known that cAMP-elevating drugs reduce permeability and
attenuate inflammatory edema. The intracellular mediators are
PKA and Epac/Rap1. PKA promotes barrier function in brain
endothelial cells through its activity on TJ and AJ proteins. In
recent years the small GTPase Rap1 has received specific atten-
tion, and the emerging picture is complex and intriguing (Kooistra
et al., 2007). Rap1 is a ubiquitous mediator that acts in a complex
signaling network to control several actin-regulated processes in
addition to the organization of cell-to-cell junctions. A coopera-
tive multifaceted relationship exists between VE-cadherin and
Rap1 in endothelial cells. Rap1 enhances the adhesive properties
of VE-cadherin (Kooistra et al., 2007). An Epac/Rap1-specific
c-AMP analog decreases monolayer permeability by increasing
VE cadherin adhesion (Fukuhara et al., 2005). On the other
hand, VE-cadherin is required for junctional recruitment of
MAGI-1, a scaffold for Rap1-activator PDZ-GEF (Sakurai et al.,
2006). Therefore Rap1 and VE-cadherin can reciprocally influ-
ence one another to modulate endothelial responses and barrier
function. Several other small GTPases are also able to modulate
AJ organization and endothelial permeability, as discussed in an
excellent and detailed review by Wojciak-Stothard and Ridley
(2002) on this subject. The picture that emerges from the many
different results published over the past few years suggests
that cadherin adhesive and signaling activities are controlled by
a complex machinery of intracellular partners (Figures 2 and 3).
Together, the components of this machinery form a dynamic
structure that can be modified and adapted according to the
functional circumstances of the cells. As discussed below, muta-
tions in many of the genes encoding the interacting components
of this complex can either directly lead to, or increase suscepti-
bility to, defects in vascular permeability and/or vascular integrity.
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At AJs, VE cadherin-b catenin complex binds different intracellular partners such as the kinase Csk which is a Src inhibitor, VEGFR-2 which may be dephosphory-
lated by the phosphatase Dep-1, TIAM which induces Rac and PAK activation, and PI3-kinase which in turn activates Akt and limit cell apoptosis. When it is
stabilized in the cytosol, free b-catenin can translocate to the nucleus and modulate cell transcription. At TJs claudins can link to members of the ZO family which
can also act as transcriptional factors. Members of the JAM family can associate to different signaling proteins which include the PAR3/PAR6 aPKC polarity
complex, ZO1, AF6/afadin, or the phosphatase MUPP1. More details are found in the text and in Liebner et al., 2006, and Vestweber, 2008.Endothelial Junctions and the Maintenance of Vascular
Integrity
There is a close relationship between the control of permeability
and vascular integrity. In many cases the opening and closure of
endothelial junctions is transient and permeability control is re-
established in a relatively short time. However, in some patholog-
ical conditions, junction dismantling may induce more dramatic
and irreversible changes in vascular integrity. One possible
reason for this is that endothelial junctions not only mediate
cell-to-cell adhesion, but can also transfer intracellular signals
that communicate cell position, limit growth and apoptosis, and
regulate vascular stability. Therefore, modifications of the molec-
ular architecture of junctions may have complex consequences
for vascular homeostasis (Dejana, 2004). Junctional complexes
trigger intracellular signals in endothelial cells in a variety of
different ways (Figure 3). They can do so directly by engaging
signaling proteins, or indirectly by limiting the nuclear transloca-
tion of proteins that modulate transcription. Examples of direct
signaling through PI3-kinase activation, mitogen-activated
protein kinase (MAPK), or small GTPases have been reported
for different cadherins (for review see Dejana, 2004). Cadherins
may also associate with growth factor receptors and modulate
their signaling properties. For instance, VE-cadherin can form
a multiprotein complex with VEGFR2 and limit its internalization
and proliferative signals (Lampugnani et al., 2006). VE-cadherin
association with the TGF-b receptor complex, however, induces
coupling of TGFb receptor II and receptor I (Alk 1 and Alk 5) and
increases TGFb signaling to inhibit cell growth and motility (Rudini
et al., 2008). In other cell types, N-cadherin has been shown tobind to the FGF receptor and reduce its internalization, although
direct evidence that this also occurs in endothelial cells is still
lacking, and E-cadherin has been shown to interact with the
EGF receptor. Together these results suggest that cadherin
modulation of cellular responses to growth factors is a general
feature of these proteins (for review see Liebner et al., 2006).
As mentioned above, junctional proteins can also shuttle from
the membrane to the nucleus to influence transcription. b-cate-
nin is a well-studied example of this paradigm. b-catenin is
a crucial member of the canonical Wnt signaling pathway, where
it modulates the transcriptional activity of lymphoid enhancer
factor (Lef-1)/T cell factor (TCF) proteins. When b-catenin is
free and stabilized in the cytoplasm it translocates to the
nucleus, displaces the transcriptional repressors Groucho/TLE
from their binding to Lef-1/TCF, and activates target gene tran-
scription (Clevers, 2006). Similarly, the armadillo protein
p120ctn also translocates to the nucleus under certain conditions
to facilitate the release of the repressor Kaiso from Lef-1/TCF
and increase target gene transcription (Park et al., 2006). In
endothelial cells, b-catenin is mainly known as a structural
component of AJs, and very little information is available on its
function in signaling. Endothelial-specific deletion of the b-cate-
nin gene in mice causes an embryonic lethal phenotype due to
alterations in vascular and heart valve development (Liebner
et al., 2004). Recent evidence indicates that Wnt/b-catenin
signaling is responsible for endothelial cell expression of blood
brain barrier characteristics (Liebner et al., 2008). By analogy
to findings in other cell types, it seems likely that when cadherins
are downregulated, or when the binding of b-catenin to theDevelopmental Cell 16, February 17, 2009 ª2009 Elsevier Inc. 213
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protein will be able to translocate to the nucleus and modulate
endothelial cell transcription. This is supported by recent work
showing that in VE-cadherin null endothelial cells or in sparsely
plated endothelial cells in culture, b-catenin signaling at the
nucleus is increased and acts in concert with FOXO1 to modu-
late gene transcription (Taddei et al., 2008). ZO proteins associ-
ated with TJs also contain several nuclear localization and export
signals. In other cell types, ZO-1 and ZO-2 become concen-
trated in the nucleus when cells are cultured in sparse condi-
tions, i.e., they do not contact each other and junctions are not
organized, or when they are exposed to stress. ZO proteins
may associate with different transcription factors such as
ZONAB, which is also found at TJs. These interactions promote
cell proliferation which is conversely limited when ZO proteins
are entrapped at the junctions (Matter and Balda, 2003).
Overall, most of the data suggest that the direct or indirect
signals transferred by junctional structures mediate cell stability.
In the endothelium this may be translated into maintenance of
vascular integrity. These observations suggest that the resting
state of endothelial cells is an active rather than constitutive/
passive condition, and that it requires complex and sustained
signaling processes for its maintenance. In support of this idea,
recent work shows that continuous and physiological FGF
signaling is required to maintain the integrity of endothelial AJs.
When FGF signaling is blocked by a soluble receptor in vitro
and in vivo, endothelial cells retract and eventually detach from
the vessel wall leading to strong alterations in vascular integrity.
This effect is mediated by phosphorylation and internalization
of VE-cadherin, which cause dismantling of junctions and endo-
thelial damage (Murakami et al., 2008).
Recent reports identified other mechanisms of inhibition of
vascular permeability mediated by the junctional recruitment of
the angiopoietin receptor Tie2 (Saharinen et al., 2008; Fukuhara
et al., 2008). However, it is still unclear whether vascular stability
mediated by these mechanisms is mediated by junctional
proteins and/or VE-cadherin in particular.
Pathologies of Vessel Morphogenesis and Junctional
Assembly
Altered vascular integrity and its major complication, bleeding,
are hallmarks of vascular malformations in human patients.
Vascular malformations are localized defects associated with
abnormal angiogenesis. Most of these defects are sporadic,
but Mendelian inheritance occurs in some families. The recent
identification of genes involved in some of these Mendelian
conditions has revealed new factors playing essential and often
unsuspected roles in angiogenesis, vascular homeostasis, and
vascular integrity. The challenge now is to determine the in vivo
function of these new genes. In a step toward this goal, increased
understanding of the mechanisms involved in vascular morpho-
genesis and vascular integrity has provided essential clues to
help decipher the mechanisms of these conditions.
Vascular malformations can affect any part of the vascular
tree, including arteries, veins, capillaries, or a combination of
these segments (for review see Brouillard and Vikkula, 2007).
They may affect any organ, but the most common and patholog-
ically significant locations are the skin, the gastrointestinal tract,
and the brain. In addition to pain and major esthetic problems,214 Developmental Cell 16, February 17, 2009 ª2009 Elsevier Inc.they may threaten life due to bleeding. In the context of this
review, we will focus on vascular malformations of the brain
(VMB) which cause serious neurological disability or death in
a significant proportion of patients due to cerebral hemorrhage.
The two main classes of VMB are brain arterio-venous malfor-
mations (BAVM) and cerebral cavernous malformations (CCM).
BAVM are high flow malformations characterized by a complex
conglomeration of dilated arteries and veins that lacks a capillary
bed and results in arteriovenous shunting (Friedlander, 2007).
Both conditions are thought to arise during embryonic, fetal,
and/or postnatal stages. Most occurrences are sporadic, but
they can also occur in families segregating as autosomal domi-
nant conditions such as capillary malformation-arteriovenous
malformations (CM-AVM) and hereditary hemorrhagic telangiec-
tasia (HHT). The gene associated with CM-AVM encodes
RASA1/p120RasGAP, a Ras GTPase activating protein which
negatively regulates the Ras MAP kinase pathway (Revencu
et al., 2008). CM-AVM patients are heterozygous for loss-of-
function mutations in this gene. However, the localized and
multifocal nature of CM-AVM lesions suggests that a somatic
second hit of this gene may be necessary for their manifestation,
as shown in other vascular hereditary malformations (Limaye
et al., 2008). Recent data on the activation of p190RhoGAP by
RASA1 and the role of the p190RhoGAP and p120-catenin in
AJ assembly has provided some clues on the possible role of
RASA1 in cell-cell junction homeostasis (Wildenberg et al.,
2006). RASA1 has also been shown to bind to and activate
Akt. However, the exact mechanisms leading to CM-AVM mal-
formations are still currently unknown. BAVM also occur in
HHT. The two HHT genes identified so far, endoglin and
ACVRL1/ALK1, encode TGFb superfamily receptors mainly
expressed in endothelial cells and are associated to VE-cadherin
(see above) (Rudini et al., 2008). The important role played by
TGFb in vascular remodeling and vessel wall integrity through
its functions in endothelial cells and differentiation of vascular
smooth muscle cells has been well established (for review see
ten Dijke et al., 2008).
CCM are slow flow malformations characterized by densely
packed vascular sinusoids embedded in a collagen matrix
without intervening neural tissue (Figures 4A and 4B). These
clusters are lined by a thin endothelium and rare subendothelial
cells. Ultrastructural analysis shows structural defects, a paucity
of endothelial cell TJs, and an absence of astrocyte end feet
within the lesions. These data suggest that the leakiness of these
lesions and the heavy hemosiderin deposits underlying the
vessels might be caused by a blood brain barrier dysfunction
(Clatterbuck et al., 2001). CCM bleeding has been involved in
10% of young patients showing intracerebral hemorrhage and
recurrent bleeding is the major risk endured by patients affected
with a familial form of the disease (FCCM), which is characterized
by lesion multiplicity (Labauge et al., 2007). The three CCM
genes identified so far (KRIT1/CCM1, MGC4607/CCM2, and
PDCD10/CCM3) encode nonhomologous proteins whose role
in angiogenesis and vascular homeostasis was completely
unsuspected. All mutations of FCCM patients lead to a loss of
function. Biallelic loss-of-function mutations are most likely
required for CCM lesions to arise (Gault et al., 2005). Recent
data strongly suggest that CCM proteins are members of a large
complex involved in cell-cell junction homeostasis and
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interact with CCM2 (Figure 2). CCM2 is a scaffold protein that
binds to actin, the GTPase Rac, and the upstream kinases
MEKK3 and MKK3, and is involved in p38 MAP kinase-mediated
control of osmolarity stress (Uhlik et al., 2003). CCM1 interacts
with ICAP1, a modulator of integrin b1, and CCM3 binds to
various STK kinases and phosphatases (Zawistowski et al.,
2002; Goudreault et al., 2008). Recent data strongly suggest
that CCM1 is a specific Rap1 effector regulating endothelial
cell-cell junctions (Glading et al., 2007). The CCM1 FERM
domain is unmasked by the activated Rap1 and controls the
junctional localization of CCM1, which has been shown to
interact with b-catenin and AF6/afadin. Interestingly, ICAP1
and CCM2 are involved in Rho GTPase pathways, which in
turn are known to regulate the integrity of tight junctions. Alto-
gether these data strongly suggest that CCM proteins may be
involved in cell-cell junction integrity.
Animal Models of Vascular Malformation Disorders
Despite the identification of the affected genes in several
inherited vascular disorders, our understanding of the mecha-
nisms underlying vascular lesion formation in these diseases is
still very incomplete. Most of the human disorders are highly
variable in penetrance and onset, and the location and timing
Figure 4. CCM Lesions from a Human Patient and Abnormal Vessel
Remodeling in a Transgenic Mouse Embryo in which CCM2 Has
Been Ablated from Endothelial Cells
(A) Cerebral MRI showing multiple CCM lesions.
(B) Surgical view of a CCM lesion.
(C and D) Whole mount PECAM staining of control (C) and transgenic embryos
(D) at E10.5 showing abnormal vascular remodeling in the aorta, outflow tract,
and head vessels.of lesion formation are unpredictable, making it impossible to
observe and study the earliest, proximal steps in disease mani-
festation. Animal models, in particular mice and zebrafish
(Figure 5A), have been critical for in vivo experimental analysis
of the molecular and cellular mechanisms underlying vascular
diseases, and have begun to yield new insights into their
etiology. We will briefly discuss, as examples, HHT and CCM
and some of the novel insights that have come from exploring
the in vivo roles of disease genes using animal models.
Animal Models of Hereditary Hemorrhagic
Telangiectasia
As discussed above, defects in the TGFb receptor superfamily
members Endoglin and ALK1 have been shown to be the causa-
tive lesions in HHT type 1 (HHT1) and HHT type 2 (HHT2), respec-
tively (Lebrin and Mummery, 2008). Murine models have been
developed for both HHT1 (Arthur et al., 2000; Bourdeau et al.,
1999) and HHT2 (Bourdeau et al., 1999; Seki et al., 2003; Urness
et al., 2000). Endoglin null embryos die at approximately E10.5
with vascular and cardiac defects (Arthur et al., 2000). Endothelial
cells are specified and the yolk sac vasculature develops into
a primitive vascular plexus, but it fails to remodel and mature
beyond this stage. Vascular channels throughout the animals
appear dilated, and the animals also develop extensive hemor-
rhaging indicative of vascular fragility. Heart defects are also
noted, with the atrioventricular canal endocardium failing to
undergo mesenchymal transformation and cushion-tissue
formation. Mice homozygous null for ALK1 also die by mid-gesta-
tion, with severe vascular malformations including fusion of major
arteries and veins (Seki et al., 2003; Urness et al., 2000) and
defects in placental vascular development (Hong et al., 2007).
As the human disorders are autosomal dominant conditions,
mice heterozygous for Endoglin or ALK1 null mutants have
been carefully examined for progressive signs of HHT-like
lesions. Although initial work suggested a very low penetrance
for lesion formation in heterozygous mice, it was found that the
incidence of lesion formation is highly dependent on genetic
background and/or the presence of additional genetic defects
(Arthur et al., 2000; Bourdeau et al., 1999; Marchuk et al.,
2003). Expression of ACVRL1 proteins harboring different muta-
tions found in human patients in either cell culture or in zebrafish
embryos confirmed that most of these mutants do not act in
a dominant-negative fashion, supporting the view that HHT is
a haploinsufficiency disorder that requires additional environ-
mental and/or genetic ‘‘triggers’’ to initiate lesion formation
(Baumer et al., 2006).
Some of the evidence obtained from murine studies has sug-
gested a role for ALK1/Endoglin signaling in arterial-venous
differentiation. In an initial study it was reported that ALK1 null
embryos develop large arterial-venous shunts, downregulate
the arterial marker ephrinB2, and display intravascular hemato-
poiesis in both veins and arteries instead of only embryonic
arteries (Urness et al., 2000). Vascular remodeling defects have
been noted in mice with defects in arterial-venous (A-V) differen-
tiation, including ephrinB2 or EphB4 (Adams et al., 1999; Gerety
and Anderson, 2002; Gerety et al., 1999; Wang et al., 1998),
Notch 1/4 (Krebs et al., 2000), Notch ligand Dll4 (Duarte et al.,
2004; Gale et al., 2004; Krebs et al., 2004), Notch effector Rbpj
and Mib, and Hey1/Hey2 double mutants (Fischer et al., 2004;
Kokubo et al., 2004; Koo et al., 2005; Krebs et al., 2004). ThisDevelopmental Cell 16, February 17, 2009 ª2009 Elsevier Inc. 215
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and for developing distinct arterial and venous vascular beds.
However, vascular remodeling defects and a failure to properly
differentiate arteries and veins have been noted in a number of
different knockout models that do not directly affect arterial-
venous differentiation, and it is not always clear that A-V
morphology defects represent proximal effects of loss of the
targeted gene as opposed to secondary consequences. Brain
arterial venous malformations most similar to those found in
HHT have not been reported so far in human patients carrying
Notch receptor/ligand mutants. Furthermore, analysis of Endo-
glin null mice showed that, unlike ALK1 mutants, they do not
show profound vessel dilation or downregulate arterial ephrinB2
(Sorensen et al., 2003). Analysis of an ALK1 LacZ knockin mouse
also showed that this gene is expressed primarily in larger
arteries (Seki et al., 2003), suggesting it probably does not
have a direct functional role in venous vessels.
A variety of recent evidence has suggested that rather than
affecting A-V identity, the proximal role of ALK1 signaling might
be to regulate proliferation and the ‘‘quiescence state’’ of the
endothelium. In a zebrafish model for HHT2, the ‘‘Violet beaure-
garde’’ mutant (Figures 5B and 5C), affected vessels did not
display any apparent defect in differentiation but did contain
many more endothelial cells than normal, indicating that the
mutant caused an endothelial over proliferation (Park et al.,
2008; Roman et al., 2002). Other work, including a recent study
Figure 5. Zebrafish Models of Hereditary
Hemorrhagic Telangiectasia, HHT, and Cerebral
Cavernous Malfomations, CCM
(A) Blood vessels are readily visualized in living zebrafish
embryos and larvae, as shown in this confocal microan-
giographic image of the vasculature of a 3 day old zebra-
fish larva.
(B and C) Confocal microangiographic images of the
cranial vasculature of 3 day old wild-type (B) and violet
beauregarde (alk1/acvrl1) mutant animals. Mutants
display highly enlarged cranial vessels with increased
numbers of endothelial cells.
(D and E) Transmitted light images of 2 day old wild-type
(D) and CCM pathway gene knockdown (E) zebrafish.
Images are: (A) Lateral view, anterior to the left, from Isogai
et al., 2001; (B and C) Dorsal view of the head, anterior to
the left; (D and E) Lateral view of the head, anterior to the
left, adapted from Gore et al., 2008.
identifying a probable in vivo ligand for ALK1
(see below), has supported the idea that
signaling through this receptor regulates the
‘‘activation state’’ of the endothelium (Park
et al., 2008). It may be that the defects in arte-
rial-venous differentiation noted in some studies
could be a secondary consequence of a general
failure of ALK1-deficient endothelial cells to
cease proliferating and take on a quiescent
differentiated state.
As noted above, ALK1 and Endoglin are TGFb
superfamily receptors and a great deal of
interest has been focused on potential signaling
upstream and downstream from these genes.
Based on a variety of evidence it has been
proposed that TGFb can activate downstream
Smad signaling through both ALK1 and ALK5 TGFb type1 recep-
tors in endothelial cells, with opposing effects. TGFb/ALK5
signaling inhibits endothelial cell migration and proliferation,
while TGFb/ALK1 signaling promotes endothelial cell migration
and proliferation, with the balance between ALK1 and ALK5
signaling regulating the cellular response (Goumans et al.,
2002). However, more recent studies have cast doubt on both
the role of opposing signaling between ALK1 and ALK5 in vivo
and whether TGFb is the physiologically relevant ligand for
ALK1. Examination of mice with lacZ knocked into either the
ALK1 or ALK5 genes revealed that they are not expressed in
the same cells; ALK1 is expressed in endothelial cells, while
ALK5 is expressed in vascular smooth muscle cells (Seki et al.,
2006). It was assumed that TGFbactivated downstream signaling
by binding to either ALK1 or ALK5 Type I receptors in combination
with the TGFb type 2 receptor (TFGbR2). However, when Alk1-cre
mice were used to perform cre-mediated restricted excision of
the ALK1, ALK5, or TGFbR2 genes, only deletion of ALK1
resulted in a vascular malformation defect (Park et al., 2008), sug-
gesting that ALK5 and TGFbR2 are not required for ALK1
signaling or involved in the pathology of HHT. Evidence from
a recent study also indicates that the likely physiological ligand
for ALK1 is BMP9, not TGFb, and that this ligand is a potent anti-
angiogenic factor (David et al., 2008). Interestingly, the results of
this paper also suggest that high levels of circulating BMP9 play
a role in maintaining adult blood vessel quiescence.216 Developmental Cell 16, February 17, 2009 ª2009 Elsevier Inc.
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As described above, human familial CCM syndromes have been
linked to mutations at three loci: CCM1/Krit1, CCM2/Malcaver-
nin, and CCM3/PDCD10. A number of studies (such as Hilder
et al., 2007; Plummer et al., 2005; Zawistowski et al., 2005)
have demonstrated that the three CCM proteins physically
interact with one another and with a variety of additional protein
partners including the small ras-family GTPase Rap1 (CCM1/
Krit1 was originally cloned by virtue of its interaction with
Rap1/Krev1, hence its name ‘‘Krev interaction trapped 1,’’ or
Krit1; Serebriiskii et al., 1997). Expression studies performed
using in situ hybridization, immunohistochemistry, or analysis
of knockin alleles have shown that all three CCM genes are simi-
larly expressed in both neurons and blood vessels in the mouse
brain (Petit et al., 2006; Plummer et al., 2006; Tanriover et al.,
2008). CCM1 and CCM2 are also expressed in blood vessels
and selected neural tissues in the zebrafish (Gore et al., 2008;
Hogan et al., 2008; Mably et al., 2006). The strong expression
of the CCM genes in neural tissue and the neural involvement
in lesion formation in CCM patients has led to suggestions that
cavernous malformations may be the result of a primary defect
in surrounding neural cells rather than blood vessel endothelial
cells (Plummer et al., 2006). As discussed below, however,
recent animal studies suggest that despite their expression in
neurons it is the endothelial function of these genes that is critical
for maintaining vascular integrity.
CCM1/Krit1 knockout mice demonstrated that this gene is
required for proper vascular development (Whitehead et al.,
2004). Homozygous mutant embryos die in mid-gestation with
dilated, thin-walled cranial vessels and enlarged caudal dorsal
aorta with an increased number of endothelial cells. Downregu-
lation of arterial-specific gene expression is also observed. The
vascular defects emerge in the absence of obvious alterations
in neural morphology or neural marker expression, leading the
authors of the initial knockout study to suggest that the primary
defect is in endothelial rather than neural cells. Like HHT, CCM is
an autosomal dominant disorder, and virtually all mutants
discovered to date in human CCM patients have been clear
loss-of-function alleles. An initial screening of heterozygous
mice failed to detect cavernous malformations. To test the
hypothesis that the occurrence of CCM lesions might require
a second somatic hit, CCM1 heterozygous mice were bred
with p53/ mice that show an increased rate of somatic muta-
tions. Vascular lesions were observed in the brains of 55% of
the double mutant animals (Plummer et al., 2004). However, no
somatic hit was detected within the CCM1 wild-type allele in
the double transgenic mutants, suggesting that the appearance
of vascular lesions might reflect a direct role of p53 deficiency in
promoting the genesis of vascular malformations. However,
a second hit in any of the two other CCM genes or interacting
genes cannot be excluded. The idea that otherwise phenotypi-
cally silent second site ‘‘hits’’ in interacting genes could be pre-
disposing to or initiating lesion formation in CCM has been
explored directly in more detail using the zebrafish (see below).
Fortuitously, a gene trap insertion was discovered in the
CCM2 gene (Plummer et al., 2006). Heterozygous gene trap
insertion mice develop cerebral vascular malformations,
although the penetrance is low, as in many murine models of
vascular malformation disorders. In heterozygotes, b-galactosi-dase from the gene-trap allele is strongly expressed in neurons
and choroid plexus as well as larger vessels, but is not clearly
visualized in vascular endothelium of small vessels in the brain
(like CCM1 and CCM3; see above), leading the authors of this
study to propose that ‘‘cerebral cavernous malformations arise
as a result of defects in the neural parenchyma surrounding
the vascular endothelial cells in the brain.’’ However, in both ze-
brafish and mice, it appears that endothelial and not neural cell
alterations are responsible for CCM lesions.
Mutants in both CCM1 (‘‘santa’’ mutants) and CCM2 (‘‘valen-
tine’’ mutants) have been isolated in the zebrafish (Mably et al.,
2006). Both of these mutants were discovered based on their
enlarged heart cardiac phenotypes (enlarged, poorly functional
hearts are also noted in homozygous CCM1-deficient mice).
Like their mammalian counterparts, the zebrafish CCM genes
are also expressed in the vasculature, and several recent studies
have examined the functional requirement for CCM genes in that
context. Loss of CCM1 or CCM2 in fish leads to defects in the
vasculature in addition to the cardiac defects, with formation of
enlarged, thin-walled vessels (Gore et al., 2008; Hogan et al.,
2008). In one report, blastomere transplantation methods were
used to show that wild-type endothelial cells could adopt
a ‘‘wild-type’’ morphology when they integrated into vessels in
CCM1 mutant animals, suggesting that CCM1 is required cell
autonomously for regulation of endothelial cell shape (Hogan
et al., 2008). An endothelial cell-autonomous requirement for
CCM1 function has also been demonstrated in zebrafish by
using transgenic endothelial-specific expression of CCM1 to
‘‘rescue’’ cranial vascular hemorrhage caused by antisense mor-
pholino-mediated knockdown of endogenous CCM1 (Gore
et al., 2008). However, recent work in the mouse has provided
what is probably the most conclusive evidence to date that the
primary defects in CCM are endothelial-specific. Ubiquitous,
endothelial-, or neural-specific CCM2 knockout mice were
generated using cre-lox technology and examined for homozy-
gous phenotypes. Animals homozygous for a ubiquitous deletion
of CCM2 die during early embryogenesis, like CCM1 knockouts.
However, despite the high level of expression of this gene in the
neuroepithelium, targeting of CCM2 in neuroglial precursor cells
does not lead to cerebrovascular defects. By contrast, endothe-
lial-specific knockout of CCM2 severely affects angiogenesis
and leads to major heart, arterial, and venous morphogenesis
defects and embryonic lethality at mid-gestation (Figures 4C
and 4D). Thus, while further analysis will be required to verify
a specific functional requirement for the other CCM genes in
endothelium versus neuroepithelium, it appears that the prox-
imal defect in CCM is probably initiated within the endothelium
(Boulday et al., 2009).
The results of a recent study in the zebrafish have also
provided new insights into the etiology of CCM (Gore et al.,
2008). As noted above, the incidence of lesion formation is highly
variable within affected CCM families, and the factors that trigger
intracranial hemorrhage (ICH) in either inherited or sporadic
forms of the disease are not understood. Not all individuals
harboring defective CCM genes develop ICH, reflecting incom-
plete penetrance of these mutations and/or involvement of addi-
tional genetic modifiers predisposing to lesion formation (Lucas
et al., 2003). As also noted above, there is ample evidence that
CCM genes act together in common intracellular complexesDevelopmental Cell 16, February 17, 2009 ª2009 Elsevier Inc. 217
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Plummer et al., 2005; Voss et al., 2007; Zawistowski et al., 2005),
suggesting that minor functional perturbations of different genes
in these complexes or pathways might act together to precipitate
ICH. However, demonstrating this sort of multigene association
is not possible in the available small human CCM pedigrees. By
injecting specialized morpholino antisense oligonucleotides into
zebrafish embryos, Gore et al. (2008) simultaneously inhibited
the expression of multiple CCM pathway genes in various
combinations. They showed that a subtle decrease in each of
these genes alone caused little or no effect independently, but
when combined resulted in very high frequencies of ICH (Figures
5D and 5E). Thus, small, individually silent defects in the CCM
pathway can strongly synergize to increase susceptibility to
ICH. These findings have important implications. Single hetero-
zygous mutations in CCM proteins may not be enough to induce
stroke, but may require accompanying subtle secondary muta-
tions to ‘‘trigger’’ lesion formation. Mutations in CCM pathway
effectors may contribute to the highly variable penetrance of
familial CCM disorders. Subtle genetic second hits in individuals
that are outwardly normal but ‘‘sensitized’’ by minor deficits in
CCM pathway genes could also lead to sporadic forms of
hemorrhagic stroke. Together, the mouse and zebrafish studies
discussed above illustrate the power of these animal models for
dissecting the in vivo functional roles of identified human
vascular malformation disease genes.
Concluding Remarks
Understanding the molecular basis for vascular malformation
disorders and the defects in vascular integrity that lead to hemor-
rhage and stroke requires a three-pronged approach. In vitro
studies are needed to study the basic cell biology of endothelial
junction formation, and probe the functional roles of genes impli-
cated in vascular pathobiology through in vivo studies in human
patients and animal models. Clinical studies are needed to iden-
tify the genetic causes of vascular disease in humans and
examine how vascular malformation lesions and endothelial
integrity defects develop in human patients. And finally, animal
models such as mice and zebrafish are a vital tool for testing
the in vivo functional roles of identified junction/vascular disease
genes, and to uncover additional interacting genes. It is impor-
tant to fully integrate together each of these approaches to
achieve a holistic understanding of the etiology of vascular mal-
formation/junctional integrity disorders and provide the greatest
opportunity for developing effective therapies to ameliorate
or prevent these conditions. In this review we have attempted
to illustrate how recent findings from each of these three
approaches can be integrated to provide progress toward this
goal.
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